Biggest News Aggregation in the World
📰 Multiple Ascending Doses News

Multiple Ascending Doses News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Multiple Ascending Doses. Real-time updates on events, politics, business and more.

EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023

/PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its...
District Of Columbia United States South Korea United Kingdom New Zealand University College

Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be...
United States Jennifer Porcelli Mike Beyer Biohaven Neuroinnovation Exchange Commission On Drug Administration

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
United States Comunidad Autonoma De Cataluna Haruo Naito Harald Hampel Randall Bateman Dennisj Selkoe

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Eisai To Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State Symposium, and Other Pipeline Assets at the AD/PD™ 2022 Annual Meeting

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimers...
United States Comunidad Autonoma De Cataluna Haruo Naito Harald Hampel Randall Bateman Dennisj Selkoe

Stoke Therapeutics Presents Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

– Single doses of STK-001 up to 30mg and multiple doses of 20mg were well tolerated with no safety concerns related to study drug – – 70.6% of patients treated with STK-001... | December 3, 2021
United Kingdom United States Elaine Wirrell Helen Cross Barry Ticho Colin Roberts

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science